<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03935854</url>
  </required_header>
  <id_info>
    <org_study_id>48527</org_study_id>
    <nct_id>NCT03935854</nct_id>
  </id_info>
  <brief_title>Impact of a Ketogenic Diet on Metabolic and Psychiatric Health in Patients With Schizophrenia or Bipolar Illness</brief_title>
  <official_title>Impact of A Low-Carbohydrate, High-Fat, Ketogenic Diet on Obesity, Metabolic Abnormalities and Psychiatric Symptoms in Patients With Schizophrenia or Bipolar Illness: An Open Pilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To initiate a low-carbohydrate, high-fat (LCHF) ketogenic dietary intervention among a small&#xD;
      cohort of outpatients with either schizophrenia or bipolar illness and comorbid&#xD;
      overweight/obesity currently taking psychotropic medications.&#xD;
&#xD;
      Adults with mental illness represent a high-risk, marginalized group in the current obesity&#xD;
      epidemic. Among US adults with severe mental illness, obesity and overweight are highly&#xD;
      prevalent conditions having severe consequences, with patients estimated to die on average 25&#xD;
      years earlier than the general population largely of premature cardiovascular disease. In&#xD;
      addition, many psychiatric medications, particularly antipsychotics and mood stabilizers, can&#xD;
      contribute to metabolic side effects and weight gain. Low-carbohydrate high-fat (LCHF) diets&#xD;
      have been shown to reduce cardiovascular risk in those with insulin resistance. The purpose&#xD;
      of this study is to evaluate both the metabolic and psychiatric outcomes with an LCHF diet in&#xD;
      this psychiatric population.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 13, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in heart rate from baseline</measure>
    <time_frame>Baseline, 16 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in blood pressure from baseline</measure>
    <time_frame>Baseline, 16 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in weight from baseline</measure>
    <time_frame>Baseline, 16 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in body fat mass from baseline</measure>
    <time_frame>Baseline, 16 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Change in Hemoglobin A1c from baseline</measure>
    <time_frame>Baseline, 16 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in insulin resistance measure (HOMA-IR) from baseline</measure>
    <time_frame>Baseline, 16 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in inflammatory marker (hsCRP) from baseline</measure>
    <time_frame>Baseline, 16 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in lipid profile (triglycerides) from baseline</measure>
    <time_frame>Baseline, 16 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in lipid profile (small dense LDL) from baseline</measure>
    <time_frame>Baseline, 16 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in lipid profile (HDL) from baseline</measure>
    <time_frame>Baseline,16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Psychiatric Indices - Mood</measure>
    <time_frame>Baseline, 16 weeks</time_frame>
    <description>Change in Mood Score (Clinical Mood Monitoring) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychiatric Indices- Clinical Global Impression</measure>
    <time_frame>Baseline, 16 weeks</time_frame>
    <description>Change in Clinical Global Impression Scales (CGI) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychiatric Indices- Global Assessment of Functioning</measure>
    <time_frame>Baseline, 16 weeks</time_frame>
    <description>Change in Global Assessment of Functioning (GAF) Scale from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychiatric Indices- Quality of Life</measure>
    <time_frame>Baseline, 16 weeks</time_frame>
    <description>Change in Manchester Quality of Life Scale (MANSA) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychiatric Indices- BPRS</measure>
    <time_frame>Baseline, 16 weeks</time_frame>
    <description>Change in Brief Psychiatric Rating Scale (BPRS) from baseline</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Obesity</condition>
  <condition>Ketogenic Dieting</condition>
  <condition>Metabolic Syndrome</condition>
  <condition>Bipolar Disorder</condition>
  <condition>Schizophrenia</condition>
  <condition>Weight Gain</condition>
  <condition>Psychotropic Drug, Unspecified Causing Adverse Effects in Therapeutic Use</condition>
  <arm_group>
    <arm_group_label>Ketogenic Diet 16 Week Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>LCHF, Ketogenic Diet</intervention_name>
    <description>Low Carbohydrate, Moderate Protein, High Fat Ketogenic Dietary Intervention 16 weeks</description>
    <arm_group_label>Ketogenic Diet 16 Week Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18-70 years old&#xD;
&#xD;
          2. Meet DSM V criteria for schizophrenia or bipolar disorder, any subtype, for &gt; 1 year&#xD;
             and clinically stable (with no hospitalization for past 3 months)&#xD;
&#xD;
          3. Currently taking psychotropic medication and gained at least 5% weight since starting&#xD;
             medication or have a BMI greater than or equal to 26 kg/m2 or presence of at least one&#xD;
             metabolic abnormality (hypertriglyceridemia, insulin resistance, dyslipidemia,&#xD;
             impaired glucose tolerance)&#xD;
&#xD;
          4. Willing to consent to all study procedures and attend follow-up appointments and&#xD;
             motivated to follow the dietary program.&#xD;
&#xD;
          5. Sufficient control over their food intake to adhere to study diets.&#xD;
&#xD;
          6. Willingness to regularly monitor blood pressure, glucose, dietary intake, and body&#xD;
             weight over the 4-month trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any subject pregnant or nursing&#xD;
&#xD;
          2. Comorbidity of developmental delay&#xD;
&#xD;
          3. Active substance abuse with illicit drugs or alcohol&#xD;
&#xD;
          4. In a current severe mood or psychotic state when entering the study that would&#xD;
             prohibit compliance with study visits or dietary program.&#xD;
&#xD;
          5. Anyone who has been hospitalized or taken clozapine over the past 3 months&#xD;
&#xD;
          6. Inability to complete baseline measurements&#xD;
&#xD;
          7. Severe renal or hepatic insufficiency&#xD;
&#xD;
          8. Cardiovascular dysfunction, including diagnosis of:&#xD;
&#xD;
               1. Congestive heart failure&#xD;
&#xD;
               2. Angina&#xD;
&#xD;
               3. Arrhythmias&#xD;
&#xD;
               4. Cardiomyopathy&#xD;
&#xD;
               5. Valvular heart disease&#xD;
&#xD;
          9. Any other medical condition that may make either diet dangerous as determined by the&#xD;
             study medical team (e.g. anorexia nervosa)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shebani Sethi Dalai, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shebani Sethi Dalai, MD</last_name>
    <phone>650-721-4419</phone>
    <email>shebanis@stanford.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kat Nameth, M.S.</last_name>
    <phone>650-721-2168</phone>
    <email>knameth@stanford.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford University Department of Psychiatry &amp; Behavioral Sciences</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kat Nameth Clinical Research Coordinator</last_name>
      <phone>650-721-2168</phone>
      <email>knameth@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Farnaz Hooshmand, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laura Saslow, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Sethi Dalai S, Sinha A, Gearhardt AN. Low carbohydrate ketogenic therapy as a metabolic treatment for binge eating and ultraprocessed food addiction. Curr Opin Endocrinol Diabetes Obes. 2020 Oct;27(5):275-282. doi: 10.1097/MED.0000000000000571. Review.</citation>
    <PMID>32773576</PMID>
  </reference>
  <reference>
    <citation>Carmen M, Safer DL, Saslow LR, Kalayjian T, Mason AE, Westman EC, Sethi Dalai S. Treating binge eating and food addiction symptoms with low-carbohydrate Ketogenic diets: a case series. J Eat Disord. 2020 Jan 29;8:2. doi: 10.1186/s40337-020-0278-7. eCollection 2020.</citation>
    <PMID>32010444</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>April 30, 2019</study_first_submitted>
  <study_first_submitted_qc>April 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 2, 2019</study_first_posted>
  <last_update_submitted>February 11, 2021</last_update_submitted>
  <last_update_submitted_qc>February 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Shebani Sethi Dalai</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Weight Gain</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

